mouse , human bace1

NB-360 is a potent and brain-penetrable inhibitor of BACE1 and BACE2 with IC50s of 5, 5, and 6 nM for mouse and human BACE1 and BACE2. NB-360 exhibits excellent selectivity over the related aspartyl proteases pepsin, cathepsin E, and cathepsin D.

Umibecestat is an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimer's disease.

Potent and selective β-secretase (BACE) inhibitor (IC50 values are 10.2 and 20.3 nM for human BACE2 and BACE1, respectively). Displays >5,000-fold selectivity for BACE over other proteases including cathepsin D, pepsin and renin. Inhibits Aβ1-40 and Aβ1-42 production in cells expressing mutated APP. Reduces hippocampal and cortical Aβ and sAPPβ levels in an Alzheimer's disease mouse model.

BuChE-IN-9 (compound 22a), an eqBuChE (equine serum-derived butyrylcholinesterase) inhibitor, exhibits potent activity with an IC50 of 173 nM. In addition to eqBuChE, it also inhibits human BACE1, Aβ aggregation, and mouse GABA transporters 1 and 4 (mGAT1 and mGAT4). Notably, BuChE-IN-9 demonstrates significant antiamnesic properties [1].